Daniela Santos-Faria1,2, Maxime Dougados3,4, Laure Gossec5, Serge Perrot6, Anna Moltó3,4. 1. Rheumatology Department, Unidade Local de Saúde do Alto Minho (ULSAM), Hospital Conde de Bertiandos, Largo Conde de Bertiandos, 4990-078, Ponte de Lima, Portugal. danielasantosfaria@gmail.com. 2. Rheumatology Department, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France. danielasantosfaria@gmail.com. 3. Rheumatology Department, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France. 4. INSERM (U1153), Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France. 5. Department of Rheumatology, Pitié-Salpêtrière Hospital, Sorbonne Universités, UPMC Université, AP-HP, Paris, France. 6. Pain Center and INSERM U987, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France.
Abstract
OBJECTIVES: The aim of the study is to evaluate the performance of extreme patient-reported outcomes (PRO) against definitions of fibromyalgia (FM) in patients with axial spondyloarthritis (axSpA). METHODS: Ancillary analysis of the Predict-SpA trial, an observational study of axSpA patients receiving TNF-α inhibitor, was performed. 'Extreme PRO' was defined as a score ≥ 8 on three out of the first five Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions (scored 0-10). FM was defined by the American College of Rheumatology (ACR) 1990 criteria and the Fibromyalgia Rapid Screening Test (FiRST). Performances of 'extreme PRO' for FM were evaluated by the sensitivity, specificity and positive likelihood ratio using the 1990 ACR criteria as gold standard. As secondary analysis, the FiRST was used as the external standard. RESULTS: The prevalence of 'extreme PRO' in this population was 28.8% at baseline and decreased to 9.9% at 12 weeks. 'Extreme PRO' had low sensitivity 12 weeks after TNF initiation (0.18, 95% confidence interval [CI] 0.10-0.27 vs 0.60, 95% CI 0.50-0.71, at baseline), but high specificity (0.92, 95% CI 0.89-0.94 vs 0.78, 95% 0.74-0.82, at baseline), using ACR 1990 criteria as gold standard. Performances when tested against FiRST at 12 weeks showed higher sensitivity (0.27, 95% CI 0.20-0.35) and specificity (0.96, 95% CI 0.94-0.98). CONCLUSION: The proposed extreme PRO definition showed great specificity for FM recognition in patients with axSpA, suggesting it could be used in observational studies when specific items for FM classification are not available.
OBJECTIVES: The aim of the study is to evaluate the performance of extreme patient-reported outcomes (PRO) against definitions of fibromyalgia (FM) in patients with axial spondyloarthritis (axSpA). METHODS: Ancillary analysis of the Predict-SpA trial, an observational study of axSpApatients receiving TNF-α inhibitor, was performed. 'Extreme PRO' was defined as a score ≥ 8 on three out of the first five Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions (scored 0-10). FM was defined by the American College of Rheumatology (ACR) 1990 criteria and the Fibromyalgia Rapid Screening Test (FiRST). Performances of 'extreme PRO' for FM were evaluated by the sensitivity, specificity and positive likelihood ratio using the 1990 ACR criteria as gold standard. As secondary analysis, the FiRST was used as the external standard. RESULTS: The prevalence of 'extreme PRO' in this population was 28.8% at baseline and decreased to 9.9% at 12 weeks. 'Extreme PRO' had low sensitivity 12 weeks after TNF initiation (0.18, 95% confidence interval [CI] 0.10-0.27 vs 0.60, 95% CI 0.50-0.71, at baseline), but high specificity (0.92, 95% CI 0.89-0.94 vs 0.78, 95% 0.74-0.82, at baseline), using ACR 1990 criteria as gold standard. Performances when tested against FiRST at 12 weeks showed higher sensitivity (0.27, 95% CI 0.20-0.35) and specificity (0.96, 95% CI 0.94-0.98). CONCLUSION: The proposed extreme PRO definition showed great specificity for FM recognition in patients with axSpA, suggesting it could be used in observational studies when specific items for FM classification are not available.
Authors: Frederick Wolfe; Daniel J Clauw; Mary-Ann Fitzcharles; Don L Goldenberg; Winfried Häuser; Robert S Katz; Philip Mease; Anthony S Russell; I Jon Russell; John B Winfield Journal: J Rheumatol Date: 2011-02-01 Impact factor: 4.666
Authors: F Wolfe; H A Smythe; M B Yunus; R M Bennett; C Bombardier; D L Goldenberg; P Tugwell; S M Campbell; M Abeles; P Clark Journal: Arthritis Rheum Date: 1990-02
Authors: Jaime C Branco; Bernard Bannwarth; Inmaculada Failde; Jordi Abello Carbonell; Francis Blotman; Michael Spaeth; Fernando Saraiva; Francesca Nacci; Eric Thomas; Jean-Paul Caubère; Katell Le Lay; Charles Taieb; Marco Matucci-Cerinic Journal: Semin Arthritis Rheum Date: 2009-02-27 Impact factor: 5.532
Authors: Diego Benavent; Dafne Capelusnik; Sofia Ramiro; Anna Molto; Clementina López-Medina; Maxime Dougados; Victoria Navarro-Compán Journal: RMD Open Date: 2022-09
Authors: Rikke A Andreasen; Lars E Kristensen; Kenneth Egstrup; Xenofon Baraliakos; Vibeke Strand; Hans Christian Horn; Inger M J Hansen; Robin Christensen; Torkell Ellingsen Journal: Arthritis Res Ther Date: 2019-10-29 Impact factor: 5.156